CalciMedica (CALC) Stock Analysis

What CalciMedica does

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.

Key metrics

ETFs linked to CALC

Broad-market and Healthcare sector ETFs an investor holding CalciMedica is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CALC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for CalciMedica?

CalciMedica trades under the ticker CALC on NASDAQ.

Which exchange is CALC listed on?

CALC is listed on NASDAQ.

What sector does CalciMedica operate in?

CalciMedica is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CALC in a portfolio?

PortView shows CALC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.